Preoperative Chemotherapy Does Not Increase Morbidity or Mortality of Hepatic Resection for Colorectal Cancer Metastases

被引:73
作者
Scoggins, Charles R. [1 ]
Campbell, Michael L. [1 ]
Landry, Christine S. [1 ]
Slomiany, Beatrix A. [1 ]
Woodall, Charles E. [1 ]
McMasters, Kelly M. [1 ]
Martin, Robert C. G. [1 ]
机构
[1] Univ Louisville, Div Surg Oncol, James Graham Brown Canc Ctr, Louisville, KY 40202 USA
关键词
PORTAL-VEIN EMBOLIZATION; LONG-TERM SURVIVAL; MULTICENTER RANDOMIZED-TRIAL; RESECTABLE LIVER METASTASES; HIGH-DOSE; 5-FLUOROURACIL; NEOADJUVANT CHEMOTHERAPY; 1ST-LINE TREATMENT; 24-HOUR INFUSION; SCORING SYSTEM; FOLINIC ACID;
D O I
10.1245/s10434-008-0190-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hepatic metastasis from colorectal cancer (mCRC) is best treated with a multidisciplinary approach. Conflicting data exist regarding the impact of preoperative chemotherapy on morbidity and mortality after hepatectomy. We hypothesized that preoperative chemotherapy does not adversely impact complications or mortality associated with hepatectomy. A retrospective analysis was performed and included patients with mCRC who underwent hepatectomy from 1996 to 2006. Patients were separated into two groups: those who received preoperative chemotherapy and those who did not. Univariate and multivariate analyses were performed to determine the factors associated with morbidity and mortality. Kaplan-Meier analyses were performed to determine disease-free survival (DFS) and overall survival (OS). One hundred eighty-six patients were analyzed: 112 (60%) received preoperative chemotherapy for a median of 4.2 months. Eighty patients (43%) underwent major hepatectomy. When comparing the two groups, there were no differences in hepatic tumor size (median 3 cm; p = 0.35), type of resection (p = 0.62), stage (p = 0.44) or location (p = 0.10) of the primary tumor, preoperative carcinoembryonic antigen (CEA) level (p = 0.80), or number of nodes in lymphadenectomy (p = 0.62). Only number of positive nodes after colectomy (p = 0.02), age (p a parts per thousand currency sign 0.0001), and combined resection/radiofrequency ablation (RFA) (p = 0.004) were statistically different between the two groups. There was no difference in rates of morbidity (p = 0.81), mortality (p = 0.29), DFS (p = 0.25) or OS (p = 0.30). We conclude that the use of preoperative chemotherapy did not increase the risk of complications or death for patients undergoing hepatectomy for metastatic colorectal cancer. Pre-hepatectomy chemotherapy appears to be safe and is an important part of the multidisciplinary approach for this disease.
引用
收藏
页码:35 / 41
页数:7
相关论文
共 33 条
[1]   Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization [J].
Abdalla, EK ;
Barnett, CC ;
Doherty, D ;
Curley, SA ;
Vauthey, JN .
ARCHIVES OF SURGERY, 2002, 137 (06) :675-680
[2]   Tumor progression while on chemotherapy - A contraindication to liver resection for multiple colorectal metastases? [J].
Adam, R ;
Pascal, G ;
Castaing, D ;
Azoulay, D ;
Delvart, V ;
Paule, B ;
Levi, F ;
Bismuth, H .
ANNALS OF SURGERY, 2004, 240 (06) :1052-1064
[3]  
Adam R, 2004, ANN SURG, V240, P644, DOI 10.1097/01.sla.0000141198.92114.16
[4]   Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases [J].
Allen, PJ ;
Kemeny, N ;
Jarnagin, W ;
DeMatteo, R ;
Blumgart, L ;
Fong, Y .
JOURNAL OF GASTROINTESTINAL SURGERY, 2003, 7 (01) :109-115
[5]   Solitary colorectal liver metastasis - Resection determines outcome [J].
Aloia, TA ;
Vauthey, JN ;
Loyer, EM ;
Ribero, D ;
Pawlik, TM ;
Wei, SH ;
Curley, SA ;
Zorzi, D ;
Abdalla, EK .
ARCHIVES OF SURGERY, 2006, 141 (05) :460-466
[6]   Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy [J].
Bismuth, H ;
Adam, R ;
Levi, F ;
Farabos, C ;
Waechter, F ;
Castaing, D ;
Majno, P ;
Engerran, L .
ANNALS OF SURGERY, 1996, 224 (04) :509-520
[7]   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].
de Gramont, A ;
Figer, A ;
Seymour, M ;
Homerin, M ;
Hmissi, A ;
Cassidy, J ;
Boni, C ;
Cortes-Funes, H ;
Cervantes, A ;
Freyer, G ;
Papamichael, D ;
Le Bail, N ;
Louvet, C ;
Hendler, D ;
de Braud, F ;
Wilson, C ;
Morvan, F ;
Bonetti, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947
[8]   Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].
Douillard, JY ;
Cunningham, D ;
Roth, AD ;
Navarro, M ;
James, RD ;
Karasek, P ;
Jandik, P ;
Iveson, T ;
Carmichael, J ;
Alakl, M ;
Gruia, G ;
Awad, L ;
Rougier, P .
LANCET, 2000, 355 (9209) :1041-1047
[9]   Preoperative selective portal vein embolization before hepatectomy for liver metastases:: Long-term results and impact on survival [J].
Elias, D ;
Ouellet, JF ;
de Baère, T ;
Lasser, P ;
Roche, A .
SURGERY, 2002, 131 (03) :294-299
[10]   Portal vein embolization before right hepatectomy - Prospective clinical trial [J].
Farges, O ;
Belghiti, J ;
Kianmanesh, R ;
Regimbeau, JM ;
Santoro, R ;
Vilgrain, V ;
Denys, A ;
Sauvanet, A .
ANNALS OF SURGERY, 2003, 237 (02) :208-217